Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Driving Performance after Bedtime Administration of Daridorexant, Assessed in a Sensitive Simulator
Clemens Muehlan, Sander Brooks, Cédric Vaillant, et al.
Clinical Pharmacology & Therapeutics (2022) Vol. 111, Iss. 6, pp. 1334-1342
Open Access | Times Cited: 20

Showing 20 citing articles:

Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder
Dieter Kunz, Yves Dauvilliers, Heike Beneš, et al.
CNS Drugs (2022) Vol. 37, Iss. 1, pp. 93-106
Open Access | Times Cited: 52
The orexin story and orexin receptor antagonists for the treatment of insomnia
Clemens Muehlan, Catherine Roch, Cédric Vaillant, et al.
Journal of Sleep Research (2023) Vol. 32, Iss. 6
Open Access | Times Cited: 39
Emerging and upcoming therapies in insomnia
W.-H. Kim, Ho-Sook Kim
Translational and Clinical Pharmacology (2024) Vol. 32, Iss. 1, pp. 1-1
Open Access | Times Cited: 6
Utilizing Technology to Enhance the Ecological Validity of Cognitive and Functional Assessments in Schizophrenia: An Overview of the State-of-the-Art
William P. Horan, Raeanne C. Moore, Heather G. Belanger, et al.
Schizophrenia Bulletin Open (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 5
Driving under the Influence: A Review of Fitness to Drive, Drug-Induced Impairments, and Simulation Testing
Lorenzo Uccello, Alessandro Nobili, Luca Pasina, et al.
SAE technical papers on CD-ROM/SAE technical paper series (2025) Vol. 1
Closed Access
Psychotropic Drugs in Special Conditions

(2025), pp. 913-926
Closed Access
The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act
Margaret Moline, Shoji Asakura, Carsten Beuckman, et al.
Psychopharmacology (2023) Vol. 240, Iss. 4, pp. 699-711
Open Access | Times Cited: 11
Daridorexant for the Treatment of Insomnia
Christopher L. Robinson, Rajesh Supra, Evan Downs, et al.
Health psychology research (2022) Vol. 10, Iss. 3
Open Access | Times Cited: 15
Daridorexant in Insomnia Disorder: A Profile of Its Use
Tina Nie, Hannah A. Blair
CNS Drugs (2023) Vol. 37, Iss. 3, pp. 267-274
Open Access | Times Cited: 8
Residual effects of medications for sleep disorders on driving performance: A systematic review and network meta-analysis of randomized controlled trials
Michele Fornaro, Claudio Caiazza, Flavia Rossano, et al.
European Neuropsychopharmacology (2024) Vol. 81, pp. 53-63
Closed Access | Times Cited: 2
Preclinical metabolism and the disposition of vornorexant/TS‐142, a novel dual orexin 1/2 receptor antagonist for the treatment of insomnia
Yoshihiro Konno, Shunsuke Kamigaso, Hidetoh Toki, et al.
Pharmacology Research & Perspectives (2024) Vol. 12, Iss. 2
Open Access | Times Cited: 2
Guideline for evaluating the effects of psychotropic drugs on motor vehicle driving performance in Japan: A tiered approach for the assessment of clinically meaningful driving impairment
Tetsuo Nakabayashi, Kunihiro Iwamoto, Akiko Yamaguchi, et al.
Neuropsychopharmacology Reports (2024) Vol. 44, Iss. 2, pp. 308-313
Open Access | Times Cited: 2
A Comprehensive Review of Daridorexant, a Dual-Orexin Receptor Antagonist as New Approach for the Treatment of Insomnia
Wojciech Ziemichód, Karolina Grabowska, Antonina Kurowska, et al.
Molecules (2022) Vol. 27, Iss. 18, pp. 6041-6041
Open Access | Times Cited: 9
Daridorexant: Comprehensive Review of A New Oral Agent for the Treatment of Insomnia
Juliane Park, Kandon P. Render, Drew W. Cates
Annals of Pharmacotherapy (2023) Vol. 57, Iss. 9, pp. 1076-1087
Closed Access | Times Cited: 5
Daridorexant: A New Dual Orexin Receptor Antagonist for Insomnia
Erin St. Onge, Bradley Phillips, Casey Rowe
Journal of Pharmacy Technology (2022) Vol. 38, Iss. 5, pp. 297-303
Open Access | Times Cited: 8
Daridorexant as a novel pharmacotherapeutic approach in insomnia: a systematic review and meta-analysis
Siddhartha Dutta, Shubha Singhal, Rima Shah, et al.
Expert Opinion on Drug Safety (2023) Vol. 22, Iss. 12, pp. 1237-1251
Open Access | Times Cited: 3
Pharmacokinetics, pharmacodynamics and safety profile of the dual orexin receptor antagonist vornorexant/TS‐142 in healthy Japanese participants following single/multiple dosing: Randomized, double‐blind, placebo‐controlled phase‐1 studies
Daiji Kambe, Sayaka Hasegawa, Yumiko Imadera, et al.
Basic & Clinical Pharmacology & Toxicology (2023) Vol. 133, Iss. 5, pp. 576-591
Open Access | Times Cited: 3
A scoping review of motor vehicle operator performance assessments for benzodiazepine receptor agonists
Andrea Murphy, Korolos Sawires, Sophie Peltekian, et al.
Exploratory Research in Clinical and Social Pharmacy (2024) Vol. 16, pp. 100538-100538
Open Access
Side effects of sedatives and hypnotics
Mei T. Liu, Daniel Greer, Megan Maroney
Side effects of drugs annual (2023), pp. 33-47
Closed Access | Times Cited: 1
Les antagonistes doubles des recepteurs de l’orexine : une nouvelle approche pharmacologique du traitement de l’insomnie chronique
Régis Lopez
Médecine du Sommeil (2022) Vol. 19, Iss. 3, pp. 195-199
Open Access | Times Cited: 1
New pharmaceuticals in the treatment of insomnia
Jozef Višňovský, Jakub Vaněk
Psychiatrie pro praxi (2023) Vol. 24, Iss. 3, pp. 176-179
Closed Access
Page 1

Scroll to top